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The global dissemination of carbapenem-resistant Enterobacteriaceae (CRE) has become an urgent 
public health concern (1,2). In 2016, the World Health 
Organization included CRE in a list of antimicrobi-
al-resistant priority pathogens on which to concen-
trate future drug development strategies. Of note, 
carbapenem-resistant Klebsiella pneumoniae (CRKP) 
account for 60%–90% of clinical CRE infections in the 
United States, Europe, and China (1–3), resulting in 
an increased mortality rate of up to 40%–50% in noso-
comial settings (4).
The dissemination of CRKP is mostly clonal, and 
the population structure is geographically specific. 
Since its emergence during the early to mid-2000s, 
sequence type (ST) 258 has become the most preva-
lent CRKP clone in North America, Latin America, 
and Europe (5). However, in Asia, especially China, 
ST11 is the predominant clone, accounting for up to 
60% of CRKP (3). ST11 is a single-locus (tonB) variant 
of ST258, and both types belong to the clonal group 
258. A recombination event is thought to have oc-
curred between a recipient ST11 and a donor ST442-
like strain, giving rise to ST258 during 1985–1997 
(6,7). A phylogenomic study revealed that the ST258 
population consists of >2 clades, resulting from an 
≈215-kb recombination event that includes the cap-
sule polysaccharide (cps) synthesis locus (6). The ge-
netic differences generated by the resulting capsular 
switch are supposed to be primarily responsible for 
the ST258 diversification (8). Likewise, a segregation 
was identified in the ST11 population, resulting in >3 
clades with different capsular loci (KL) (9–11). These 
studies consistently indicate that cps is a recombina-
tion hotspot in K. pneumoniae. However, the K-type 
distribution within ST11 in clinical settings is unclear. 
More important, the biological, epidemiologic, and 
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We aimed to clarify the epidemiologic and clinical impor-
tance of evolutionary events that occurred in carbapen-
em-resistant Klebsiella pneumoniae (CRKP). We collect-
ed 203 CRKP causing bloodstream infections in a tertiary 
hospital in China during 2013–2017. We detected a sub-
clonal shift in the dominant clone sequence type (ST) 
11 CRKP in which the previously prevalent capsular loci 
(KL) 47 had been replaced by KL64 since 2016. Patients 
infected with ST11-KL64 CRKP had a significantly higher 
30-day mortality rate than other CRKP-infected patients. 
Enhanced virulence was further evidenced by phenotyp-
ic tests. Phylogenetic reconstruction demonstrated that 
ST11-KL64 is derived from an ST11-KL47–like ancestor 
through recombination. We identified a pLVPK-like viru-
lence plasmid carrying rmpA and peg-344 in ST11-KL64 
exclusively from 2016 onward. The pLVPK-like–positive 
ST11-KL64 isolates exhibited enhanced environmental 
survival. Retrospective screening of a national collection 
identified ST11-KL64 in multiple regions. Targeted sur-
veillance of this high-risk CRKP clone is urgently needed. 
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clinical importance of capsular switches in ST11 re-
mains poorly understood.
Of greater concern, a carbapenem-resistant hy-
pervirulent K. pneumoniae ST11 outbreak clone was 
recently reported in eastern China (12). The outbreak 
strain was KL47 and hypermucoid and harbored a 
virulence plasmid carrying rmpA2 and the aerobac-
tin synthesis locus. Loss of the plasmid substantially 
alleviated virulence in a Galleria mellonella moth mod-
el. This finding indicates a worrying convergence of 
carbapenem resistance and hypervirulence in an al-
ready epidemic lineage of K. pneumoniae. Although 
incidence of carbapenem-resistant hypervirulent K. 
pneumoniae has remained low (13–15), understanding 
how this lineage emerged and evolved is crucial in 
controlling its further dissemination.
In this study, we measured the occurrence and 
clinical outcomes of bloodstream infections (BSI) 
caused by CRKP in a tertiary hospital in China 
during 2013–2017. We characterized the genomic 
alterations in the dominant ST11 population and 
ascertained associated changes in phenotype and 
pathogenicity traits.
Materials and Methods
Setting and Study Design
We performed a retrospective study in a 2,500-bed ter-
tiary care hospital in China during January 2013–June 
2017. We reviewed medical records of any patient with 
a blood culture positive for K. pneumoniae and a clinical 
course consistent with bacteremia (upon notification of 
the patient). Patients <16 years of age were excluded. If 
1 patient had >1 episode of BSI caused by K. pneumoni-
ae (BSI-KP), we included only the first episode. This 
study was approved by the institutional review board 
of the First Affiliated Hospital of Zhejiang University 
in China (approval no. 2017–442). Definitions of terms 
are detailed in Appendix 1 (https://wwwnc.cdc.gov/
EID/article/26/2/19-0594-App1.pdf).
Microbiological Assessment
We determined antimicrobial susceptibility by us-
ing the VITEK-II system (bioMérieux, https://www.
biomerieux.com) and further confirmed by using the 
broth microdilution method. We defined carbapenem 
nonsusceptibility as MIC >2 mg/L for imipenem or 
meropenem or MIC >1 mg/L for ertapenem (16). We 
used multilocus sequence typing to identify ST11 
(17). We estimated the pathogenicity of K. pneumoni-
ae by testing G. mellonella infection, biofilm produc-
tion, and neutrophil-killing resistance, as previously 
described (18–20) (Appendix 1). We evaluated the 
capacity of CRKP to survive on dry surfaces over time 
by using previously described methods (21), except 
that the stainless steel discs were replaced by Corn-
ing 24-well polystyrene microplates (Merck, https://
www.sigmaaldrich.com) and the concentration of 
bacteria was adjusted to 1 × 108 CFU/mL.
Whole-Genome Sequencing and Analyses
We sequenced 154 ST11 isolates by using an Illumina 
Hiseq2500 instrument (Illumina, https://www.illu-
mina.com) with 2 × 125-bp paired-end libraries. We 
performed de novo assembly of the short-read data by 
using CLC Genomics Workbench version 10.0 (QIA-
GEN, https://www.qiagen.com) after quality trim-
ming (Phred quality score >20). We performed long-
read sequencing on 2 isolates (KP16932 and KP47434) 
by using the PacBio RSII platform (Pacific Biosciences, 
https://www.pacb.com) with a 10-kb library. A hy-
brid assembly of these 2 isolates was generated by us-
ing Unicycler 0.4.0 (22) with the short and long reads. 
We annotated the assemblies by using the RAST serv-
er (https://rast.nmpdr.org) and conducted multilocus 
sequence typing by using the CGE server (https://cge.
cbs.dtu.dk). We performed plasmid analysis by South-
ern blotting and Blast (Appendix 1). We determined 
the presence or absence of resistance and virulence 
genes by using Ariba (23) with a custom gene data-
base (https://figshare.com/s/94437a301288969109c2) 
and identified K-type by using Kleborate (https://
github.com/katholt/Kleborate). We further detect-
ed mutations in rmpA and rmpA2 by using blastn 
(https://blast.ncbi.nlm.nih.gov/Blast.cgi). We in-
cluded genome assemblies of the isolates sequenced 
in this study and the 62 isolates published elsewhere 
(10–12,24–26) in the phylogenetic and temporal analy-
sis (Appendix 2 Table 1, https://wwwnc.cdc.gov/
EID/article/26/2/19-0594-App2.xlsx).
Statistical Analysis
Statistical analyses are described in Appendix 1. We 
conducted all statistical analyses by using SPSS Sta-
tistics 23 (IBM, https://www.ibm.com) and SAS 9.4 
(SAS institute, https://www.sas.com).
Results
Capsular Switch in CRKP-ST11 over a 4-Year Period
We retrospectively screened 10,134 K. pneumoniae 
isolates to determine the proportion of BSI-CRKP. 
Of 705 nonrepetitive bloodstream isolates, 203 were 
CRKP. The proportion of K. pneumoniae and CRKP 
in BSIs increased from 17.1% to 45.5% during the 
study period (Table 1). ST11 was the predominant 
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clone among BSI-CRKP isolates, accounting for 85.7% 
(n = 174); annual distribution was relatively stable 
(95.2%–91.1%).
Five KLs were detected in the BSI-CRKP-ST11 
population: KL47 (n = 76), KL64 (n = 92), KL31 (n 
= 3), KL103 (n = 2), and KL105 (n = 1). The ratio of 
ST11-KL47 to CRKP-ST11 dropped from 90% (18/20) 
in 2013 to 12.2% (5/41) in 2017, whereas that of ST11-
KL64 increased from 4.6% (1/20) in 2013 to 87.8% 
(36/41) in 2017. Thus, the ratio of ST11-KL47 to ST11-
KL64 decreased substantially in the study period (Ta-
ble 1), suggesting a KL shift among the CRKP-ST11 
population over the 4-year period.
ST11-KL64 Infections as Cause of Higher  
30-Day Mortality
To evaluate the clinical importance of ST11-KL47 
and ST11-KL64, we analyzed 162 ST11-infected pa-
tients with complete clinical data, 72 patients with 
ST11-KL47 and 90 with ST11-KL64 (Appendix 2 
Table 2); 4 ST11-KL47–infected and 2 ST11-KL64–
infected outpatients were excluded. ST11-KL47 pa-
tients had a significantly longer stay than did ST11-
KL64 patients, with respect to both the total hospital 
stay (p = 0.001) and hospital stay before the BSI on-
set (p = 0.029). More ST11-KL47–infected patients 
acquired lung infections and received invasive pro-
cedures, devices, or both before and after BSI; they 
also had received hemodialysis and chemotherapy 
or radiotherapy within 30 days before BSI. How-
ever, the Charlson comorbidity score was identical 
for patients of both groups. Patients infected with 
ST11-KL64 showed significantly higher overall 30-
day mortality than those with ST11-KL47 (62.2% vs. 
52.8%; 2 = 4.252; p = 0.039) (Figure 1).
We further included 29 patients infected with non-
ST11 CRKP in the analysis to evaluate whether CRKP-
ST11 caused higher mortality than non-ST11 CRKP. 
We found no significant differences in 30-day mortality 
between patients infected with CRKP-ST11 and those 
with non-ST11 CRKP (57.1% vs. 44.8%; χ2 = 0.833; p = 
0.176). Cox regression multivariate analysis revealed 
3 factors independently associated with a higher risk 
for ST11-caused mortality: lower platelet at time of 
BSI, Acute Physiology and Chronic Health Evaluation 
(APACHE II) score, and tigecycline as the empirical 
therapy (Table 2; Appendix 2 Table 3). We also found 
no significant difference in 30-day mortality between 
patients infected with ST11-KL47 and those with non-
ST11 CRKP (52.8% vs. 44.8%; 2 = 0.395; p = 0.529). 
However, the ST11-KL64–infected patients showed 
significantly higher 30-day mortality than those with 
non-ST11 CRKP (62.2% vs. 44.8%; 2 = 3.771; p = 0.05).
Recombination-Mediated Evolutionary  
Diversification in CRKP-ST11
We performed phylogenomic analysis to understand 
the evolutionary diversification in the CRKP-ST11 
population. We included 154 newly sequenced ge-
nomes (excluding the remaining 20 isolates with-
out rmpA or rmpA2); 62 previously published ST11 
genomes from diverse origins; and an ST1731 genome 
(accession no. ERR1541319) as an outgroup. We identi-
fied 429 recombined regions, including 348 that were 
>1 kb. The length of sequence removed per isolate 
ranged from 505,312 to 1,276,214 bp (median 947,836 
bp). The phylogenetic tree, which was rooted using the 
ST1731 outgroup isolate that was later removed (Ap-
pendix 1 Figure 1), showed division of ST11 isolates 
into 2 major clades (Figure 2). One clade consists of 
isolates of KL47, KL64, and KL31 exclusively obtained 
from China, whereas the second clade consists of iso-
lates possessing diverse K-types from elsewhere. These 
findings suggest that KL47 and KL64 have emerged 
and undergone local expansion in China. 
Root-to-tip regression analysis of the 154 new-
ly sequenced genomes demonstrated a correlation 
between the genetic distances and sampling dates 
(R2 = 0.64) (Appendix 1 Figure 2). By using a Bayes-
ian dating method implemented in BactDating (27), 
we found that KL64 isolates probably evolved from 
a KL47 ancestor around 2011 (Appendix 1 Figure 3). 
A high substitution rate also was found (15.3 single-
nucleotide polymorphisms (SNPs)/genome/y, 95% 
CI 12.4–19.0 SNPs/genome/y).
The number of SNPs separating ST11-KL47 and 
ST11-KL64 isolates was 907–3,098 before and 30–220 
after removal of recombination regions. This finding 
suggests that recombination largely contributed to the 
diversification of ST11-KL47 and ST11-KL64. Indeed, 
 
Table 1. Prevalence trend of Klebsiella pneumoniae causing BSIs in a tertiary hospital, China, 2013–2017* 
Isolate type 2013 2014 2015 2016 2017 (half year) 
Score test 
for trend p value† 
Primary BSI/non-BSI isolates 123/610 133/635 201/723 149/687 99/398 1.3934 0.1635 
CRKP/non-CRKP 21/102 35/98 53/148 49/100 45/54 6.0697 <0.001 
CRKP-ST11/non-ST11 CRKP 20/1 28/7 46/7 39/10 41/4 −0.3116 0.7553 
ST11-KL47/ST11-KL64 18/1 20/4 22/23 11/28 5/36 −7.5463 <0.001 
*BSI, bloodstream infection; CRKP, carbapenem-resistant Klebsiella pneumoniae; ST, sequence type.  
†Calculated by using Chochran–Armitage trend test. 
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we detected 4 recombination events of >1 kb on the 
branch coinciding with the switch from KL47 to KL64 
(regions with respect to the reference genome [iso-
late KP47434]: 307,448–322,057; 4,060,806–4,154,013; 
4,173,036–4,186,742; and 4,197,111–4,217,597) (Ap-
pendix 1 Figure 4; Appendix 2 Table 4). Three of these 
events were localized around the cps region, suggest-
ing that the capsule switch was likely the result of re-
combination. Another recombination event in the cps 
region also corresponds with the capsule switch from 
KL47 to KL31 (Appendix 1 Figure 4).
Emergence of rmpA-rmpA2–Positive  
ST11-KL64 Isolates
Analysis of virulence genes showed that the 154 ST11 
isolates possessed yersiniabactin genes (ybtAEPQS-
TUX, irp1, irp2, and fyuA) located on ICEKp3, and 
the core type III fimbrial cluster mrkABCDF, except 
for 4 ST11-KL64 isolates. Of 76 ST11-KL47 isolates, 29 
(36.3%) carried an rmpA2 gene, and only 2 were posi-
tive for the string test, suggesting that rmpA2 was inac-
tive in most isolates. rmpA2-positive ST11-KL47 isolates 
have been detected since 2013 and are interspersed 
among rmpA2-negative isolates in the phylogenetic 
tree (Figure 2). A frameshift rmpA2 gene (rmpA2*) 
was identified in 48 of 92 ST11-KL64 isolates (52.2%). 
rmpA2*-positive ST11-KL64 isolates were first detected 
in 2015, and most of them are monophyletic (Figure 2). 
An rmpA gene was also found in 42 of the 48 rmpA2*-
positive ST11-KL64 isolates, of which 6 had in-frame 
truncations resulting in 2 variants (555 bp and 624 
bp) and 12 were positive for the string test. The rmpA- 
rmpA2*–positive ST11-KL64 isolates were detected 
from 2016 onward. The prevalence trend of rmpA/
rmpA2-positive isolates is accordant with that of each 
subclone (Appendix 1 Figure 5).
All rmpA/rmpA2*-positive isolates also carried 
aerobactin genes iucABCD-iutA, implying that they 
might co-locate on the same plasmid. A plasmid-
borne virulence factor peg-344 was exclusively found 
in 45 of 48 rmpA2*-positive ST11-KL64 isolates. The 
salmochelin cluster iroBCDN was also detected in 5 
rmpA-rmpA2*-positive and in 1 classic ST11-KL64 iso-
late (Figure 2).
Diversity of Virulence Plasmids
We further analyzed the vectors of rmpA/rmpA2 
genes to understand how they were captured. The 
rmpA/rmpA2 gene of both subclones was detected on 
plasmids by using southern blot (Appendix 1 Figure 
6). Higher diversity of the virulence plasmids was 
found in ST11-KL64 through classifying the plasmids 
by size; 5 types were detected in ST11-KL47 with siz-
es ranging from 110 to 217 kb, and 13 types were in 
ST11-KL64, ranging from 110 to 230 kb (Appendix 2 
Table 5). The rmpA and rmpA2* genes coexisted on the 
same plasmid in ST11-KL64.
Virulence plasmids detected in KP16932 (KL47) 
and KP47434 (KL64) were circularized to evaluate 
their structural variations. The rmpA2 gene of KP16932 
was carried by an IncFIB(K)-IncHI1B–type plasmid 
(pVir-KP16932) with a size of 177.8 kb, which is al-
most identical to a virulence plasmid pVir-CR-HvKP4 
(MF437313) recently detected in a KL47 clone that 
caused a fatal outbreak in China (Appendix 1 Figure 
Figure 1. Kaplan–Meier survival estimates for patients with 
bloodstream infections caused by ST11-KL47, ST11-KL64, and 
non-ST11 CRKP, China, 2013–2017. A significant difference was 
found in the 30-day mortality among the 3 groups (p = 0.039). 
ST11-KL64–infected patients showed significantly higher overall 
30-day mortality than ST11-KL47–infected patients (62.2% 
vs. 52.8%; p = 0.039) and non-ST11 CRKP–infected patients 
(62.2% vs. 44.8%; p = 0.05). No significant difference in 30-day 
mortality was found between patients infected with ST11-KL47 
and non-ST11 CRKP (52.8% vs. 44.8%, p = 0.529). CRKP, 
carbapenem-resistant Klebsiella pneumoniae; KL, capsular loci; 
ST, sequence type.
 
Table 2. Multivariable analysis of risk factors for 30-day mortality 
in 191 BSI patients infected with carbapenem-resistant Klebsiella 
pneumoniae, China, 2013–2017* 
Variable p value† OR (95% CI) 
Platelets at time of BSI 0.001 0.996  
(0.994–0.998) 
APACHE II score at time of BSI 0.012 1.041  
(1.009–1.074 
Tigecycline as empirical therapy 0.003 1.920  
(1.257–2.935) 
*APACHE, Acute Physiology and Chronic Health Evaluation; BSI, 
bloodstream infection; OR, odds ratio. 
†Calculated by using Cox regression. 
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7). The rmpA and rmpA2* genes of KP47434 existed in 
an IncFIB(K)-IncHI1B–type plasmid (pVir-KP47434) 
with a size of 201.8 kb, which shares a high homology 
with a virulence plasmid pVir-CR-HvKP267 (accession 
no. MG053312). Compared with pVir-KP47434, a 24-
kb and an 18-kb region were absent in pVir-KP16932 
(Appendix 1 Figure 7), which encodes genes involved 
in metabolic processes such as carbon utilization (Op-
pA-B-F and DppC) (28) and virulence (H-NS protein) 
(29). The virulence plasmids carried by rmpA2-KL47 
and rmpA/rpmA2*-KL64 isolates possessed the highly 
similar backbone sequences with the pVir-KP16932 
and pVir-KP47434 plasmids, respectively, and the 
intra-subclonal variations were mainly caused by gain or 
loss of gene clusters involved in heavy metal resistance 
and mobile genetic elements (Appendix 1 Figure 8).
Virulence Plasmids and Infections
To evaluate whether the acquisition of virulence plas-
mids carrying rmpA/rmpA2 and aerobactin genes has 
an effect on clinical outcomes, we stratified the cohort 
described according to the existence of virulence plas-
mids in ST11-KL47 and ST11-KL64. No significant dif-
ferences in mortality were evident between patients 
infected by ST11-KL64-pVir-KP47434–like or classical 
ST11-KL64 isolates (i.e., without virulence plasmids) 
Figure 2. Phylogenetic analysis of 216 CRKP ST11 isolates, China, 2013–2017, including 154 CRKP isolates collected during 2012–2017 
in study of bloodstream infections in a tertiary hospital and 62 isolates that were sequenced in previous studies (Appendix 2 Table 1, 
https://wwwnc.cdc.gov/EID/article/26/2/19-0594-App2.xlsx). The phylogenetic tree was obtained by mapping all sequence reads to 
the hybrid assembly of KP47434 and removing the recombined regions from the alignment. The tree was rooted using ST1731 isolate 
EuSCAPE_ES29 (ERR1541319), which was included in this analysis but later removed from the tree (a tree including this outgroup is 
shown in Appendix 1 Figure 1, https://wwwnc.cdc.gov/EID/article/26/2/19-0594-App1.pdf). Five capsular types (KL31, KL47, KL64, KL103, 
and KL105) were detected in our ST11 collection, which are indicated in different colors as shown in the legend. Some of virulence genes 
detected are shown here. The rmpA2 gene carried by KL64 isolates was frameshifted, namely rmpA2*. Aerobactin and salmochelin 
represent the iucABCD-iutA and iroBCDN gene clusters, respectively. The fatal outbreak clone reported in China recently (12) is highlighted 
on the tree. Lanes: 1, year; 2, country; 3, K-type; 4, rmpA; 5, rmpA2; 6, aerobactin; 7, peg-344; 8, salmochelin; 9, blaKPC. Scale bar 
indicates single-nucleotide polymorphisms. CRKP, carbapenem-resistant Klebsiella pneumoniae; KL, capsular loci; ST, sequence type.
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(60.4% vs. 64.3%; p = 0.983) or those infected by ST11-
KL47-pVir-KP16932 or classical ST11-KL47 isolates 
(51.7% vs. 53.5%; p = 0.931) (Appendix 2 Table 6, 7). 
However, the Charlson comorbidity scores for pa-
tients with ST11-KL47-pVir-KP16932–like infections 
(median 1 [range 0.5–2]) were significantly lower than 
scores for patients with ST11-KL47 infections (median 
3 [range 1–4]; p = 0.003); similarly, scores for ST11-
KL64-pVir-KP47434–like patients (median 1 [range 
0–2]) were significantly lower than scores for ST11-
KL64 patients (median 2 [range 1–3]; p = 0.003). These 
findings indicate that the virulence plasmids could 
promote infections in healthier patients.
Various Resistomes in ST11-KL47 and ST11-KL64
The resistome of ST11-KL47 was different from that 
of ST11-KL64 (Appendix 1 Figure 9). Genes floR, 
arr-3, dfrA27, and aac(6’)-Ib-cr were exclusively 
detected in ST11-KL47, whereas blaSHV-12 and 
dfrA14 were unique for ST11-KL64, suggesting the 
2 subclones might have been selected for in different 
niches. For each subclone, the resistomes of rmpA/
rmpA2-positive isolates were much more consistent 
than those of classical isolates (Appendix 1 Figure 9). 
This finding is consistent with the phylogeny and the 
fact that the rmpA/rmpA2-positive isolates were rela-
tively more clonal.
Enhanced Virulence in ST11-KL64
The rmpA/rmpA2-encoding virulence plasmids carried 
by each subclone shared an intrasubclonal similarity 
as described previously (i.e., the intrasubclonal varia-
tions were mainly caused by gain or loss of heavy metal 
resistance gene clusters and mobile genetic elements). 
ST11-KL64 isolates produced significantly more bio-
film than ST11-KL47 isolates (optical density at 595 nm: 
0.54 + SD 0.09 vs. 3.08 + SD 0.11; p<0.0001) (Appendix 1 
Figure 10, panel A). We evaluated the virulence poten-
tial by using a human neutrophil assay. The ST11-KL64 
isolates had an average survival of 91.2% after incuba-
tion with the human neutrophils for 60 min, which was 
significantly higher than that of the ST11-KL47 strains 
(65.8%; p = 0.0011) (Appendix 1 Figure 10, panel B). 
Compared with the ST11-KL64 isolates, the ST23-K1 
isolates showed lower survival (70.3%) and the ST86-
K2 isolates comparable survival (91.8%). The ST35 iso-
late had the lowest survival, 37.2%. 
We further estimated pathogenicity by infecting G. 
mellonella larvae with an inoculum of 1 × 106 CFU. At 
48 h postinfection, the 4 ST11-KL64 isolates (1 classic 
[isolate KP33068], 1 rmpA2*-positive [isolate KP33130], 
and 2 rmpA-rmpA2*-positive [isolates KP33229 and 
KP33367]) showed comparable virulence resulting in 
10% survival, whereas survival was 40%–60% for the 
4 ST11-KL47 isolates (2 classic [isolates KP9343 and 
KP29407] and 2 rmpA2-positive [isolates KP10042 and 
KP16932]). K1 survival 40% and K2 30%; survival of a 
classic CRKP isolate (ST35) reached 70% (Appendix 1 
Figure 10, panel C).
To determine the underlying mechanisms of en-
hanced transmissibility obtained by rmpA-rmpA2*– 
positive ST11-KL64, we randomly selected 6 ST11-KL47 
isolates (3 classic [KP8369, KP29407, and KP30412] and 
3 rmpA2-positive [KP9343, KP10042, and KP16932]) and 
6 ST11-KL64 isolates (2 classic [KP28367 and KP33068], 
2 rmpA2*-positive [KP33130 and KP45812], and 2 rmpA-
rmpA2*–positive [KP47434 and KP39615]) to evaluate 
the capacity of survival on a dry polystyrene surface. 
Only viable cells of 2 rmpA-rmpA2*-KL64 isolates were 
recovered after overnight drying; the average recovered 
loads were 90 + 31.09 CFU/mL and 115 + 20.62 CFU/
mL. This finding suggests that the enhanced transmis-
sibility of the newly emerged subclone was associated 
with enhanced environmental survival.
National Prevalence of BSI-CRKP-ST11
To estimate the national prevalence of BSI-CRKP-
ST11, we further retrospectively screened 1,098 clini-
cal BSI-KP strains collected from 13 provinces in 
China during 2014–2016 (Table 3). In total, 46 of 83 
CRKP strains were ST11; ST11-KL47 accounted for 
80.4% and ST11-KL64 19.6%. The rmpA2 gene was de-
tected in 11 ST11-KL47 and 1 ST11-KL64 isolates, and 
1 isolate of each subclone also co-harbored an rmpA 
gene. The rmpA2-positive isolates were detected from 
Anhui and Zhejiang provinces. Most (9/12) rmpA2-
positive CRKP isolates appeared after 2015.
Discussion
The global dissemination of CRKP poses a serious 
threat to public health. Control of CRKP in popula-
tions and healthcare networks thus becomes an ur-
gent issue. However, efforts are often complicated by 
rapid evolution, especially among epidemic clones 
(e.g., ST11 and ST258). Therefore, tracking of evolu-
tionary events and understanding their clinical im-
portance are critical. We performed a comprehensive 
study to provide insight into the evolution of key vir-
ulence features of BSI-CRKP collected in China. We 
found 2 major KLs (KL47 and KL64) in the dominant 
clone BSI-CRKP-ST11. Capsule is known as an impor-
tant immune-evasion molecule, and thus has become 
a popular target for vaccine design. Determining the 
prevalence of KLs is crucial for the development of 
capsule-based vaccines and phage-derived exopoly-
saccharide-depolymerase treatments, which are 
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considered as novel approaches for the treatment of 
CRKP infections (30). Our study provides useful data 
for assisting the development of an immunotherapy 
for ST11-CRKP infections in China.
In this study, ST11 was partitioned into 2 clades, 
1 consisting of ST11-KL47, ST11-KL64, and ST11-
KL31, suggesting that these strains were diversified 
from a common ancestor. We found that sequences 
within the cps region of ST11-KL64 and ST11-KL31 
were imported through recombination indicating 
the occurrence of capsule switching. By using a 
Bayesian approach, we found that ST11-KL64 might 
have emerged from an ST11-KL47–like ancestor in 
2011. We further noted that the 2 ST11 subclones 
(ST11-KL47 and ST11-KL64) have spread nationally 
by interregional transmission. However, the lack of 
genome data about ST11-KL47 and ST11-KL64 from 
different origins hampers our understanding of spa-
tial evolution at a global scale.
The notion of a rapid evolution of the ST11 pop-
ulation is supported by numerous cps variants (n = 
19) and the very high evolutionary rate (15.3 SNPs/
genome/year) detected in this study and others (9). 
Capsule switching has been suggested to be a com-
mon event across the wider K. pneumoniae popula-
tion through large recombination events (9–11). We 
suppose that generating numerous descendants 
with various combinations of evolved chromosomes 
and capsules heavily contributes to the success of 
ST11 and its descendants (e.g., ST258). Of note, our 
study identified a clonal replacement in the CRKP-
ST11 population over a 4-year period in a hospital. 
ST11-KL47, the dominant subclone before 2015, was 
progressively replaced by ST11-KL64. The popula-
tion structure of ST11-K64 was monophyletic, im-
plying that ST11-KL64 might have gained fitness 
and was ready to disseminate clonally like ST258. 
Also, KL64 is a more commonly observed capsule 
type than KL47, and has been detected in Brazil 
(25), Taiwan (31), Singapore (32), the United States, 
and Europe (33).
To understand the clinical importance of the 
clonal replacement that coincided with the capsu-
lar switch in the ST11 population, we analyzed the 
metadata of 162 infected patients. Patients infected 
by ST11-KL64 had significantly higher mortality 
rates than those infected by ST11-KL47 and non-ST11 
CRKP. This finding is supported by the results of our 
phenotypic assays, which showed that ST11-KL64 
was more virulent than ST11-KL47. Our findings sug-
gest that the acquisition of virulence plasmids pro-
motes the infection in healthier patients but is not as-
sociated with the increased mortality, indicating that 
other virulence factors might be involved. Capsular 
switching in the ST11 population might contribute to 
increased mortality. The capsule type is thought to 
be an important determinant for the pathogenicity of 
K. pneumoniae, like the notorious capsular serotypes 
K1 and K2. Similar associations are also identified 
in other species, such as Acinetobacter baumannii (34) 
and Streptococcus spp. (35,36). We also cannot exclude 
that the enhanced virulence and increased mortal-
ity might be associated with other chromosomal and 
plasmid variations.
We further noted that the newly emerged rmpA2*-
positive ST11-KL64 isolates exclusively carried an 
rmpA gene. The presence of a truncated variant might 
confer an advantage through a more subtle activation 
of capsule expression in comparison to a strain with 
2 fully functional variants present (37). In addition, 
the combination of RmpA and truncated RmpA2 was 
previously found predominantly in clinical isolates 
with a hypervirulent or hypermucoviscous pheno-
type (38). This finding is consistent with our study, 
given that rmpA-rmpA2*-ST11-KL64 isolates become 
the dominant clone after they emerged. We suppose 
that such combination might confer fitness to the 
population resulting in the replacement of rmpA2-
ST11-KL47 by rmpA-rmpA2*-ST11-KL64. This suppo-
sition can be supported by the fact that rmpA-rmpA2*-
ST11-KL64 isolates survive longer than ST11-KL47 
in vitro, which largely facilitates a better dissemina-
tion of the population under nosocomial conditions. 
Besides the isolates found in Anhui and Zhejiang 
provinces in our study, 2 rmpA-rmpA2*-ST11-KL64 
isolates have been detected in Shanghai and Henan 
provinces (9), suggesting that the newly emerged 
subclone has widely disseminated in China.
In summary, our study identified the emergence 
of a high-risk subclone of CRKP-ST11, resulting in 
 
Table 3. Prevalence of CRKP-ST11 causing BSIs, China, 2014–2016* 
Year KP CRKP CRKP-ST11 
CRKP-ST11-KL47, 
rmpA/rmpA2-positive 
CRKP-ST11-KL64, 
rmpA/rmpA2-positive 
2014 224 10 7 5 (1) 2 (0) 
2015 345 31 19 16 (2) 3 (0) 
2016 529 42 20 16 (8) 4 (1) 
Total 1,098 83 46 37 (11) 9 (1) 
*Isolates were collected as part of national surveillance for BSIs. BSI, bloodstream infection; CRKP, carbapenem-resistant Klebsiella pneumoniae;  
KL, capsular loci; KP, Klebsiella pneumoniae; ST, sequence type.  
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enhanced virulence and transmissibility. The newly 
emerging descendant obtained enhanced environmen-
tal survival and poses a substantial threat to healthcare 
networks, suggesting the urgent need for tailor-made 
surveillance and stricter infection-control measures to 
prevent further dissemination in nosocomial settings.
Acknowledgments
We thank Jinru Ji and Chaoqun Ying for their assistance 
during sample collection and data analysis.
This work was supported by the National Key Research 
and Development Program of China (grant no. 
2017YFC1200200), Major Infectious Diseases such as AIDS 
and Viral Hepatitis Prevention and Control Technology  
Major Projects (grant no. 2018ZX10712-001), and the 
National Natural Science Foundation of China (81702045, 
81361138021).
We deposited the 2 scaffolded genome sequences in  
GenBank under the accession nos. QVAN00000000 
(KP16932) and QURI00000000 (KP47434); accession  
numbers of the other genome sequences are listed in  
Appendix 2 Table 1. The datasets supporting the  
conclusions of this article are included in the article and in 
Appendix 2.
About the Author
Dr. Kai Zhou is an associate professor at the First Affiliated 
Hospital of Southern University of Science and  
Technology, Shenzhen, China. His research interests are 
epidemiology and drug-resistance mechanisms of  
carbapenem-resistant Enterobacteriaceae.
References
  1. Guh AY, Bulens SN, Mu Y, Jacob JT, Reno J, Scott J, et al.  
Epidemiology of carbapenem-resistant Enterobacteriaceae 
in 7 US communities, 2012–2013. JAMA. 2015;314:1479–87. 
https://doi.org/10.1001/jama.2015.12480
  2. Grundmann H, Glasner C, Albiger B, Aanensen DM,  
Tomlinson CT, Andrasević AT, et al.; European Survey of 
Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) 
Working Group. Occurrence of carbapenemase-producing 
Klebsiella pneumoniae and Escherichia coli in the European 
survey of carbapenemase-producing Enterobacteriaceae  
(EuSCAPE): a prospective, multinational study. Lancet  
Infect Dis. 2017;17:153–63. https://doi.org/10.1016/ 
S1473-3099(16)30257-2
  3. Zhang R, Liu L, Zhou H, Chan EW, Li J, Fang Y, et al. 
Nationwide surveillance of clinical carbapenem-resistant 
Enterobacteriaceae (CRE) strains in China. EBioMedicine. 
2017;19:98–106. https://doi.org/10.1016/j.ebiom.2017.04.032
  4. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP.  
Outcomes of carbapenem-resistant Klebsiella pneumoniae 
infection and the impact of antimicrobial and adjunctive 
therapies. Infect Control Hosp Epidemiol. 2008;29:1099–106. 
https://doi.org/10.1086/592412
  5. Pitout JDD, Nordmann P, Poirel L. Carbapenemase- 
producing Klebsiella pneumoniae, a key pathogen set for global 
nosocomial dominance. Antimicrob Agents Chemother. 
2015;59:5873–84. https://doi.org/10.1128/AAC.01019-15
  6. Chen L, Mathema B, Pitout JDD, DeLeo FR, Kreiswirth BN. 
Epidemic Klebsiella pneumoniae ST258 is a hybrid strain. 
MBio. 2014;5:e01355–14.
  7. Gaiarsa S, Comandatore F, Gaibani P, Corbella M,  
Dalla Valle C, Epis S, et al. Genomic epidemiology of  
Klebsiella pneumoniae in Italy and novel insights into the 
origin and global evolution of its resistance to carbapenem 
antibiotics. Antimicrob Agents Chemother. 2015;59:389–96.
  8. DeLeo FR, Chen L, Porcella SF, Martens CA, Kobayashi SD, 
Porter AR, et al. Molecular dissection of the evolution of 
carbapenem-resistant multilocus sequence type 258 Klebsiella 
pneumoniae. Proc Natl Acad Sci U S A. 2014;111:4988–93. 
https://doi.org/10.1073/pnas.1321364111
  9. Wyres KL, Gorrie C, Edwards DJ, Wertheim HFL, Hsu LY, 
Van Kinh N, et al. Extensive capsule locus variation and 
large-scale genomic recombination within the Klebsiella  
pneumoniae clonal group 258. Genome Biol Evol. 2015;7: 
1267–79. https://doi.org/10.1093/gbe/evv062
10. Jiang Y, Wei Z, Wang Y, Hua X, Feng Y, Yu Y. Tracking a 
hospital outbreak of KPC-producing ST11 Klebsiella  
pneumoniae with whole genome sequencing. Clin Microbiol Infect. 
2015;21:1001–7. https://doi.org/10.1016/j.cmi.2015.07.001
11. Dong N, Zhang R, Liu L, Li R, Lin D, Chan EW-C, et al. 
Genome analysis of clinical multilocus sequence type 11  
Klebsiella pneumoniae from China. Microb Genom. 2018;4:54–
12. https://doi.org/10.1099/mgen.0.000149
12. Gu D, Dong N, Zheng Z, Lin D, Huang M, Wang L, et al.  
A fatal outbreak of ST11 carbapenem-resistant hypervirulent 
Klebsiella pneumoniae in a Chinese hospital: a molecular  
epidemiological study. Lancet Infect Dis. 2018;18:37–46. 
https://doi.org/10.1016/S1473-3099(17)30489-9
13. Du P, Zhang Y, Chen C. Emergence of carbapenem- 
resistant hypervirulent Klebsiella pneumoniae. Lancet  
Infect Dis. 2018;18:23–4. https://doi.org/10.1016/ 
S1473-3099(17)30625-4
14. Yao H, Qin S, Chen S, Shen J, Du X-D. Emergence of  
carbapenem-resistant hypervirulent Klebsiella pneumoniae. 
Lancet Infect Dis. 2018;18:25. https://doi.org/10.1016/ 
S1473-3099(17)30628-X
15.  Wong MHY, Shum H-P, Chen JHK, Man M-Y, Wu A,  
Chan EW-C, et al. Emergence of carbapenem-resistant  
hypervirulent Klebsiella pneumoniae. Lancet Infect Dis. 
2018;18:24. https://doi.org/10.1016/S1473-3099(17)30629-1
16. Xiao T, Yu W, Niu T, Huang C, Xiao Y. A retrospective,  
comparative analysis of risk factors and outcomes in 
carbapenem-susceptible and carbapenem-nonsusceptible 
Klebsiella pneumoniae bloodstream infections: tigecycline 
significantly increases the mortality. Infect Drug Resist. 
2018;11:595–606. https://doi.org/10.2147/IDR.S153246
17. Diancourt L, Passet V, Verhoef J, Grimont PAD, Brisse S. 
Multilocus sequence typing of Klebsiella pneumoniae  
nosocomial isolates. J Clin Microbiol. 2005;43:4178–82. 
https://doi.org/10.1128/JCM.43.8.4178-4182.2005
18. McLaughlin MM, Advincula MR, Malczynski M,  
Barajas G, Qi C, Scheetz MH. Quantifying the clinical 
virulence of Klebsiella pneumoniae producing carbapenemase 
Klebsiella pneumoniae with a Galleria mellonella model and a 
pilot study to translate to patient outcomes. BMC Infect Dis. 
2014;14:31. https://doi.org/10.1186/1471-2334-14-31
19. Naparstek L, Carmeli Y, Navon-Venezia S, Banin E. Biofilm 
formation and susceptibility to gentamicin and colistin of 
extremely drug-resistant KPC-producing Klebsiella  
 Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 26, No. 2, February 2020 297
Carbapenem-Resistant Klebsiella pneumoniae ST11
pneumoniae. J Antimicrob Chemother. 2014;69:1027–34. 
https://doi.org/10.1093/jac/dkt487
20. Wang L, Shen D, Wu H, Ma Y. Resistance of hypervirulent 
Klebsiella pneumoniae to both intracellular and extracellular 
killing of neutrophils. PLoS One. 2017;12:e0173638.  
https://doi.org/10.1371/journal.pone.0173638
21. Havill NL, Boyce JM, Otter JA. Extended survival of  
carbapenem-resistant Enterobacteriaceae on dry surfaces. 
Infect Control Hosp Epidemiol. 2014;35:445–7.  
https://doi.org/10.1086/675606
22. Wick RR, Judd LM, Gorrie CL, Holt KE. Unicycler:  
Resolving bacterial genome assemblies from short and long 
sequencing reads. PLoS Comput Biol. 2017;13:e1005595. 
https://doi.org/10.1371/journal.pcbi.1005595
23. Henson SP, Boinett CJ, Ellington MJ, Kagia N, Mwarumba S,  
Nyongesa S, et al. Molecular epidemiology of Klebsiella 
pneumoniae invasive infections over a decade at Kilifi County 
Hospital in Kenya. Int J Med Microbiol. 2017;307:422–9. 
https://doi.org/10.1016/j.ijmm.2017.07.006
24. Holt KE, Wertheim H, Zadoks RN, Baker S, Whitehouse CA, 
Dance D, et al. Genomic analysis of diversity, population 
structure, virulence, and antimicrobial resistance in Klebsiella 
pneumoniae, an urgent threat to public health. Proc Natl Acad 
Sci U S A. 2015;112:E3574–81. https://doi.org/10.1073/
pnas.1501049112
25. Bowers JR, Kitchel B, Driebe EM, MacCannell DR, Roe C, 
Lemmer D, et al. Genomic analysis of the emergence and 
rapid global dissemination of the clonal group 258 Klebsiella 
pneumoniae pandemic. PLoS One. 2015;10:e0133727.  
https://doi.org/10.1371/journal.pone.0133727
26. Moradigaravand D, Martin V, Peacock SJ, Parkhill J.  
Evolution and epidemiology of multidrug-resistant Klebsiella 
pneumoniae in the United Kingdom and Ireland. MBiol 
2017;8:e01976-16.
27. Didelot X, Croucher NJ, Bentley SD, Harris SR, Wilson DJ. 
Bayesian inference of ancestral dates on bacterial  
phylogenetic trees. Nucleic Acids Res. 2018;46:e134–4. 
https://doi.org/10.1093/nar/gky783
28. Lee E-M, Ahn S-H, Park J-H, Lee J-H, Ahn S-C, Kong I-S. 
Identification of oligopeptide permease (opp) gene cluster in 
Vibrio fluvialis and characterization of biofilm production by 
oppA knockout mutation. FEMS Microbiol Lett. 2004;240:21–
30. https://doi.org/10.1016/j.femsle.2004.09.007
29. Ares MA, Fernández-Vázquez JL, Rosales-Reyes R,  
Jarillo-Quijada MD, von Bargen K, Torres J, et al. H-NS 
nucleoid protein controls virulence features of Klebsiella 
pneumoniae by regulating the expression of type 3 pili and 
the capsule polysaccharide. Front Cell Infect Microbiol. 
2016;6:13. https://doi.org/10.3389/fcimb.2016.00013
30. Kobayashi SD, Porter AR, Freedman B, Pandey R, Chen L, 
Kreiswirth BN, et al. Antibody-mediated killing of carbapenem-
resistant ST258 Klebsiella pneumoniae by human neutrophils. 
MBio. 2018;9:1198. https://doi.org/10.1128/mBio.00297-18
31. Pan Y-J, Lin T-L, Lin Y-T, Su P-A, Chen C-T, Hsieh P-F,  
et al. Identification of capsular types in carbapenem- 
resistant Klebsiella pneumoniae strains by wzc sequencing  
and implications for capsule depolymerase treatment.  
Antimicrob Agents Chemother. 2015;59:1038–47.  
https://doi.org/10.1128/AAC.03560-14
32. Koh TH, Cao D, Shan QY, Bacon A, Hsu LY, Ooi EE.  
Acquired carbapenemases in Enterobactericeae in Singapore,  
1996–2012. Pathology. 2013;45:600–3. https://doi.org/ 
10.1097/PAT.0b013e3283650b1e
33. Cryz SJ Jr, Mortimer PM, Mansfield V, Germanier R.  
Seroepidemiology of Klebsiella bacteremic isolates and  
implications for vaccine development. J Clin Microbiol.  
1986; 23:687–90.
34. Jones CL, Clancy M, Honnold C, Singh S, Snesrud E,  
Onmus-Leone F, et al. Fatal outbreak of an emerging clone 
of extensively drug-resistant Acinetobacter baumannii with 
enhanced virulence. Clin Infect Dis. 2015;61:145–54.  
https://doi.org/10.1093/cid/civ225
35. Melin M, Trzciński K, Meri S, Käyhty H, Väkeväinen M.  
The capsular serotype of Streptococcus pneumoniae is more 
important than the genetic background for resistance to 
complement. Infect Immun. 2010;78:5262–70.  
https://doi.org/10.1128/IAI.00740-10
36. Rukke HV, Kalluru RS, Repnik U, Gerlini A, José RJ,  
Periselneris J, et al. Protective role of the capsule and impact 
of serotype 4 switching on Streptococcus mitis. Infect Immun. 
2014;82:3790–801. https://doi.org/10.1128/IAI.01840-14
37. Struve C, Roe CC, Stegger M, Stahlhut SG, Hansen DS, 
Engelthaler DM, et al. Mapping the evolution of  
hypervirulent Klebsiella pneumoniae. MBio. 2015;6:e00630. 
https://doi.org/10.1128/mBio.00630-15
38. Hsu C-R, Lin T-L, Chen Y-C, Chou H-C, Wang J-T. The role 
of Klebsiella pneumoniae rmpA in capsular polysaccharide  
synthesis and virulence revisited. Microbiology. 
2011;157:3446–57. https://doi.org/10.1099/mic.0.050336-0
Address for correspondence: Yonghong Xiao, First Affiliated 
Hospital of Zhejiang University, Qingchun Rd 79, Hangzhou, 
Zhejiang 330003, China; email: xiaoyonghong@zju.edu.cn
